AstraZeneca Pharmaceuticals LP
About AstraZeneca Pharmaceuticals LP
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
YEAR FOUNDED:
1999
What Science Can Do
2090 articles with AstraZeneca Pharmaceuticals LP
-
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
-
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
-
It was another busy week for clinical trials. Here’s a look.
-
The approval was based on data from the Phase III GRECO clinical trial and the Phase I AMES trial.
-
The U.S. Food and Drug Administration (FDA) rejected the company's inhaled triple-combination therapy, PT010, now known as Breztri Aerosphere.
-
PARP inhibitors will be taking center stage at the European Society of Medical Oncology Congress as rival drugmakers aim to show off data that supports broader use of the drug in treating various cancers.
-
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
-
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
-
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
The importance of artificial intelligence and machine learning is ever-increasing in the world of drug development and AstraZeneca is bolstering its participation in the tech revolution by striking a deal with New York-based Schrodinger to use that company’s advanced computing platform to help ac...
-
Clinical Catch-Up: August 25-30
9/3/2019
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories. -
AstraZeneca had a big weekend, with positive results from two separate clinical trial programs causing stock to jump 3.4%.
-
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
-
Breztri Aerosphere is a triple combination drug of budesonide, glycopyrronium and formoterol fumarate.
-
FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease
8/27/2019
AstraZeneca announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
-
AstraZeneca said the FDA awarded the designation to Farxiga to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
-
Sobi has Entered Into Agreement to Sell Priority Review Voucher
8/22/2019
Swedish Orphan Biovitrum AB has entered into an agreement to sell a US Food and Drug Administration Priority Review Voucher to AstraZeneca for a total cash consideration of USD 95 M.
-
The Phase III NEPTUNE trial assessed the combination treatment as a first-line treatment in an “all-comers population,” with the primary analysis population being patients with a high tumor mutational burden.
-
AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.
-
Clinical Catch-up for August 12-16
8/19/2019
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.